Health Condition 1: N33- Bladder disorders in diseases classified elsewhere
Conditions
Interventions
Sponsors
Pfizer Products India Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: All patients of high risk NMIBC who both initiated treatment and/or diagnosed Jan 2023 onwards. All patients of metastatic urothelial carcinoma who initiated treatment and/or diagnosed Jan 2023 onwards. Aged at least 18 years upon diagnosis.
Exclusion criteria
Exclusion criteria: Previously enrolled in an interventional trial related to High-risk NMIBC or mUC
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival (OS) outcomes of patients with High-risk NMIBC and mUC treated at tertiary care institutions in India. (The percentage of people in the study who are still alive for a certain period of time after they were diagnosed with or started treatment for cancer).Timepoint: 18 Months | — |
Secondary
| Measure | Time frame |
|---|---|
| To understand the baseline characteristics of the patient/disease status To understand the treatments received and reasons for change To understand the laboratory investigations if available To understand the frequency and severity of adverse events Timepoint: 18 Months | — |
Countries
India
Contacts
Public ContactDr Antara Chaudhri
Pfizer Products India Private Limited
Outcome results
None listed